Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, signed a memorandum of understanding with the Saudi Health Council to reassess mental health policies and enhance related services in the Kingdom. The MoU was signed on Dec. 12, 2024 by Dr. Mushabab Al-Assiri, acting director general of health economics and policies at SHC, and Abdallah Hamed, general manager and head of human pharma Saudi Arabia, Gulf and East Africa at Boehringer Ingelheim, during an official ceremony.
The strategic partnership serves as a platform for the exchange of global expertise to foster innovation and bring the latest research and mental health treatment models to the forefront of Saudi Arabia’s mental health strategy. The agreement is a testament to the commitment of the SHC and the Saudi government to prioritize mental health in line with Vision 2030, which aims to improve healthcare services for the citizens and residents of the Kingdom.
Hamed said: “At Boehringer Ingelheim, we continuously look to strengthen our collaborative efforts with the public sector to create science-based solutions that support patients, their families and healthcare systems in the communities we serve. Our most recent collaboration with the Saudi Health Council underscores our commitment to advancing mental health awareness, education, and treatment options in Saudi Arabia. We are proud to support the Kingdom’s Vision 2030 and to contribute to the development of a more robust mental health ecosystem that addresses the needs of the community.”
The partnership highlights the importance of collaboration between public and private sector entities to achieve common goals and advance national agendas, including community health and well-being.
The long-term goals of the partnership include developing robust policies that address the population’s needs regarding mental health disorders. These policies aim to improve public knowledge, reduce the stigma around mental health conditions, and focus on evidence-based practices to enhance access to care and clinical outcomes for patients by collaborating and aligning with various stakeholders, including policymakers, healthcare professionals, and patient advocacy groups.